ESMO 2018: Survival Results From STAMPEDE: Local Radiotherapy in Newly Diagnosed Metastatic Prostate Cancer With Low Disease Burden
Radiotherapy to the prostate improved overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden, but not in those with higher burden of disease, according to results from a preplanned analysis of a large comparison study reported by Parker et al at the European Society for Medical Oncology (ESMO) 2018 Congress (Abstract LBA5_PR).
“Standard treatment for men newly diagnosed with metastatic prostate cancer is currently drug treatment alone,” explained lead author Chris Parker, MD, Clinical Oncologist at The Royal Marsden NHS Foundation Trust, Sutton, in a statement. “Although outcomes have improved, men still typically die from metastatic prostate cancer within around 5 years, so there is a need for more effective treatment. We wanted to know if radiotherapy to the prostate might not only improve local control, but also slow progression of metastatic disease.”
STAMPEDE Trial
The multi-arm, multistage STAMPEDE trial included a randomized phase III comparison to test whether radiotherapy to the prostate improves overall survival in men with newly diagnosed metastatic prostate cancer. This was based on the hypothesis that primary tumors could contribute to overall disease progression and shorter survival in men with metastatic prostate cancer.
The study included 2,061 patients (median age = 68 years) from the UK and Switzerland who were newly diagnosed with metastatic prostate cancer. They were randomly allocated to standard of care (SOC) treatment consisting of lifelong androgen deprivation therapy plus early docetaxel from 2016, or to SOC plus radiotherapy to the prostate. The radiotherapy schedule was 55 Gy/20 fractions daily over 4 weeks or 36 Gy/6 fractions weekly over 6 weeks.
Results showed that prostate radiotherapy improved failure-free survival (hazard ratio [HR] = 0.76, 95% confidence interval [CI] = 0.68–0.84) but not overall survival (HR = 0.92, 95% CI = 0.80–1.06) in the whole group of patients.
Prespecified subgroup analysis showed that radiotherapy to the prostate improved overall survival by just over one-third (32%) in the 819 men with a low burden of metastatic disease (HR = 0.68, 95% CI = 0.52–0.90). In contrast, overall survival was not improved with radiotherapy in the 1,120 men with higher metastatic burden. Higher burden of disease in prostate cancer is defined as four or more bone metastases with at least one outside the axial skeleton and/or visceral metastases (Sweeney et al, The New England Journal of Medicine).
Radiotherapy to the prostate was well tolerated, with 5% of patients having grade 3–4 adverse events during treatment and 4% following treatment.
“There was a small increase in risk of bladder and bowel side effects, but these were modest,” said Dr. Parker.
“Prostate radiotherapy improves the survival of men with metastatic prostate cancer who have a low disease burden,” concluded Dr. Parker. He added, “Prostate radiotherapy, in addition to drug treatment, should now be a standard treatment option for men with oligometastatic disease.”
He also added that the study results are also relevant to men with pelvic node–positive but nonmetastatic disease (N1M0), where addition of radiotherapy to drug treatment could be curative.
Commentary
Commenting on the findings for ESMO, Karim Fizazi, MD, PhD, of Gustave Roussy Institute, University of Paris Sud, France, said, “For the first time, this study provides evidence that treating the local primary tumor is associated with improvement in overall survival in men with metastatic prostate cancer and minimal disseminated disease.” He added that the finding that there was no significant increase in overall survival in men with higher burden of disease was in line with the previously reported HORRAD trial.
Considering the implications for clinical practice, Dr. Fizazi suggested, “For men with newly diagnosed oligometastatic prostate cancer, it is quite likely that this data is practice-changing.” Looking to the future, he said, “For men with higher burden of disease, more data are needed regarding whether upfront local treatment improves or prevents local symptoms, which, by itself, may justify its use in the absence of an overall survival benefit.”
In terms of limitations, Dr. Fizazi noted that although the study was a large, randomized phase III trial, only 18% of the patients had received early docetaxel and none had received early abiraterone, although these treatments are now part of standard treatment in fit men.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
